Panobinostat

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelodysplastic Syndromes (MDS)

Conditions

Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML)

Trial Timeline

Aug 1, 2012 → May 1, 2014

NCT ID

NCT01613976

About Panobinostat

Panobinostat is a phase 1 stage product being developed by Novartis for Myelodysplastic Syndromes (MDS). The current trial status is completed. This product is registered under clinical trial identifier NCT01613976. Target conditions include Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML).

What happened to similar drugs?

7 of 19 similar drugs in Myelodysplastic Syndromes (MDS) were approved

Approved (7) Terminated (7) Active (7)

✅decitabine + azacitidineEisaiApproved

✅DeferasiroxNovartisApproved

✅ICL670/DeferasiroxNovartisApproved

✅deferasiroxNovartisApproved

✅DeferasiroxNovartisApproved

✅Epoetin betaRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02568943	Pre-clinical	Completed	—	—	Multiple Myeloma
NCT02204553	Pre-clinical	Completed	—	—	Multiple Myeloma
NCT02722941	Phase 2	Completed	Jun 10, 2016	Jan 18, 2021	Multiple Myeloma
NCT01802879	Phase 2	Completed	Jun 24, 2013	Nov 19, 2018	Hematologic Neoplasms
NCT01680094	Phase 1/2	Completed	Sep 1, 2012	Jan 1, 2014	HIV Infection
NCT01613976	Phase 1	Completed	Aug 1, 2012	May 1, 2014	Myelodysplastic Syndromes (MDS)
NCT01324635	Phase 1	Terminated	May 1, 2012	Oct 1, 2016	Recurrent Glioma
NCT01242774	Phase 1	Completed	Oct 1, 2010	May 1, 2014	Acute Myeloid Leukemia (AML)
NCT01115036	Phase 2	Withdrawn	Apr 1, 2010	Apr 1, 2012	Recurrent Glioblastoma
NCT00931762	Phase 2	Terminated	Aug 31, 2009	Aug 29, 2011	Primary Myelofibrosis
NCT00742027	Phase 2	Completed	Sep 16, 2008	Aug 12, 2013	Classical Hodgkin's Lymphoma
NCT00670553	Phase 1	Completed	Sep 1, 2008	Jan 1, 2010	Prostate Cancer
NCT00667862	Phase 2	Completed	Mar 18, 2008	Nov 5, 2010	Prostate Cancer
NCT00594230	Phase 2	Terminated	Jan 1, 2008	Mar 1, 2011	Myelodysplastic Syndromes (MDS)
NCT00490776	Phase 2	Terminated	Jul 5, 2007	Sep 22, 2009	Cutaneous T-Cell Lymphoma
NCT00425555	Phase 2	Completed	Jan 1, 2007	Jun 1, 2013	Cutaneous T-Cell Lymphoma

Competing Products

20 competing products in Myelodysplastic Syndromes (MDS)

See all competitors

Product	Company	Stage	Hype Score
NEX-18a injection + Azacitidine Injection	Nanexa AB	Phase 1	23
JSP191	Jasper Therapeutics	Phase 1	11
Humanized anti-CD117 Monoclonal Antibody (JSP191)	Jasper Therapeutics	Phase 1	15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	14
Erlotinib Hydrochloride	Astellas Pharma	Phase 2	35
Decitabine + Decitabine + Decitabine	Eisai	Phase 2	35
Decitabine + Valproic Acid	Eisai	Phase 2	35
decitabine + decitabine	Eisai	Phase 2	35
decitabine + azacitidine	Eisai	Approved	35
Decitabine	Eisai	Phase 2	27
decitabine + decitabine + decitabine + decitabine	Eisai	Phase 1	29
Decitabine, Arsenic Trioxide and Ascorbic Acid	Eisai	Phase 2	35
Subcutaneous Decitabine	Eisai	Phase 1	21
Decitabine	Eisai	Phase 2	35
Galunisertib + Placebo	Eli Lilly	Phase 2/3	38
DSP-7888	Sumitomo Pharma	Phase 1/2	32
TP-0184	Sumitomo Pharma	Phase 1/2	24
Decitabine	Johnson & Johnson	Phase 2	35
Epoetin alfa	Johnson & Johnson	Phase 2	27
ZARNESTRA, tipifarnib, R115777	Johnson & Johnson	Phase 2	35